Daan Gene Co Ltd

Daan Gene Co Ltd has a total equity of CNY 7.14 billion and a total debt of CNY 179.41 million, resulting in a debt-to-equity ratio of 0.03, which is significantly lower than the industry median. The company's liquidity is assessed as medium, with a current ratio of 2.82, indicating a strong short-term liquidity position.

The company's profitability is underperforming, with a return on equity (ROE) of -10.43% and a return on assets (ROA) of -8.75%. These figures are well below the industry median for ROE and ROA, which are typically positive for firms in the medical equipment and biotechnology sectors. The company reported a net loss of CNY 744.38 million for the period, driven by an operating loss of CNY 758.71 million.

Daan Gene's revenue is primarily concentrated in its domestic market, with no significant international revenue disclosed. The company operates in a single business segment focused on diagnostic products, which accounts for all of its revenue. This lack of diversification increases its exposure to domestic regulatory and economic shifts.

The company's growth trajectory is mixed. While it reported a revenue of CNY 757.66 million, the operating cash flow of CNY 319.49 million contrasts with a negative free cash flow of CNY -730.08 million, driven by capital expenditures of CNY -238.90 million. The outlook for the current fiscal year is uncertain, with no clear direction provided in the data.

The risk assessment indicates a medium liquidity risk, primarily due to the company's negative net cash position after accounting for total debt. The dilution risk is assessed as low, with no significant dilution potential identified in the basic shares outstanding. However, the company's operating losses and negative net income raise concerns about its long-term financial stability.

Recent events include a decline in profitability, as reflected in the operating and net losses. The company's ESG profile is mixed, with a low governance score of 12.82 and a high ESG controversies score of 100.00, indicating potential governance and reputational risks.

Daan Gene Co Ltd (002030.SZ) has been formally classified within the Healthcare economic sector, specifically under the Healthcare Services & Equipment activity. This taxonomic update provides a clearer definition of the company’s operational focus, aligning its profile with industry standards for healthcare providers and equipment manufacturers. In terms of risk assessment, the company now exhibits a low dilution risk. This classification suggests that the likelihood of significant share count increases that could erode existing shareholder value is currently minimal, offering a degree of stability for equity holders. Conversely, the liquidity risk has been assessed as medium. This indicates that while the company is not facing immediate distress, there are moderate considerations regarding the ease of trading its shares or accessing liquid capital, which investors should monitor alongside its operational metrics. The company currently has one analyst covering its performance, though it holds no index memberships and has no reported top holders or officers in the available data. These structural details, combined with the new risk and sector classifications, form the baseline for evaluating Daan Gene’s market position.